SCHEMBL17065907

SCHEMBL17065907

Clc1cccc2c1Nc1ccccc1-c1ccccc1-2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.50
NSD2 O96028 1/20 0.50
BCHE P06276 1/20 0.50
DAO P14920 1/20 0.50
GALR3 O60755 1/20 0.41
TGM2 P21980 1/20 0.39
MAPT P10636 1/20 0.38
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
GSK3B P49841 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
PDGFRA P16234 1/20 0.38
FER P16591 1/20 0.38
LTK P29376 1/20 0.38
CDK8 P49336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17881837 0.83 GABRP (0.47) CES1NSD2BCHEDAOTGM2
SCHEMBL17882314 0.81 GABRA1 (0.49) CES1NSD2BCHEDAOTGM2
SCHEMBL20557580 0.79 ALDH1A1 (0.41) CES1NSD2BCHEDAOGALR3
SCHEMBL8209672 0.79 CES1 (0.59) CES1NSD2BCHEDAOGALR3
SCHEMBL17065894 0.78 CES1 (0.48) CES1NSD2BCHEDAOGALR3
SCHEMBL11875403 0.77 ALDH1A1 (0.43) CES1NSD2BCHEDAOGALR3
SCHEMBL10935244 0.77 PDGFRA (0.60) CES1NSD2BCHEDAOGALR3
SCHEMBL30776834 0.75 ALDH1A1 (0.42) MAPTMAOAMAOBPDGFRAFER
SCHEMBL17882327 0.74 HPGD (0.43) CES1NSD2BCHEDAOMAPT
SCHEMBL17816635 0.74 LRRK2 (0.59) CES1BCHEMAPTGSK3BCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3237387-B1 HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES MERCK PATENT GMBH (DE) 2023-09-06 EP disclosed
EP-3237387-B1 HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES MERCK PATENT GMBH (DE) 2023-09-06 EP disclosed
US-10636979-B2 Heterocyclic compounds with dibenzazapine structures MERCK PATENT GMBH (DE) 2020-04-28 US disclosed
US-10636979-B2 Heterocyclic compounds with dibenzazapine structures MERCK PATENT GMBH (DE) 2020-04-28 US disclosed
US-20180331301-A1 HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRUCTURES MERCK PATENT GMBH (DE) 2018-11-15 US disclosed
WO-2016102039-A1 HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES MERCK PATENT GMBH (DE) 2016-06-30 WO disclosed
WO-2015133808-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME 주식회사 두산 2015-09-11 WO disclosed
WO-2015133808-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME 주식회사 두산 2015-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10636979-B2 Heterocyclic compounds with dibenzazapine structures DDT, MAOA, MAOB CES1 2893/4885NSD2 330/4885BCHE 144/4885
US-20180331301-A1 HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRUCTURES DDT, MAOA, MAOB CES1 2893/4885NSD2 330/4885BCHE 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.